Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4204–4206.

https://doi.org/10.1182/blood-2022-164811

Published: 2022

Journal Articles

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, Aránzazu Alonso Alonso, Hang Quach, Youngil Koh, Andreas Guenther, Chang-Ki Min, Xiaoou L. Zhou, Morrys Kaisermann, Lukasz M. Mis, Danaè Williams, Anne Yeakey, Geraldine Ferron-Brady, David J. Figueroa, Brandon E. Kremer, Ira Gupta, Wojciech Janowski

Blood (2021) 138 (Supplement 1): 2738.

https://doi.org/10.1182/blood-2021-153315

Published: 2021

Journal Articles

First Infection with Absidia Corymbifera in a CLL Patient - Ibrutinib As Risk Factor?

Matthes Marquardt, MD, Maren Thiel, MD, Silke Kerl, MD, Michael Wöhlke, MD, Katrin Gröpler, MD, Dietrich Gläser, MD, Andreas Guenther, MD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-135961

Published: 2020

Journal Articles

Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)

Blood (2018) 132 (Supplement 1): 1019.

https://doi.org/10.1182/blood-2018-99-113340

Published: 2018

Journal Articles

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Anna Sophie Hartjen, Andreas Krumbholz, MD, Florian Thieme, PhD, Natalie Schub, MD, Andreas Humpe, MD, Michaela Kotrova, Monika Brüggemann, MD, Martin Gramatzki, MD, Andreas Guenther, MD

Blood (2017) 130 (Supplement 1): 5490.

https://doi.org/10.1182/blood.V130.Suppl_1.5490.5490

Published: 2017

Journal Articles

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

Blood (2016) 128 (22): 5692.

https://doi.org/10.1182/blood.V128.22.5692.5692

Published: 2016

Journal Articles

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2016) 128 (22): 4471.

https://doi.org/10.1182/blood.V128.22.4471.4471

Published: 2016

Journal Articles

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Blood (2016) 127 (6): 713–721.

https://doi.org/10.1182/blood-2015-09-665018

Published: 2016

Includes: Supplemental data

Journal Articles

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2015) 126 (23): 3026.

https://doi.org/10.1182/blood.V126.23.3026.3026

Published: 2015

Journal Articles

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Blood (2015) 126 (23): 4230.

https://doi.org/10.1182/blood.V126.23.4230.4230

Published: 2015

Journal Articles

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Blood (2014) 124 (21): 4742.

https://doi.org/10.1182/blood.V124.21.4742.4742

Published: 2014

Journal Articles

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood (2014) 124 (21): 2120.

https://doi.org/10.1182/blood.V124.21.2120.2120

Published: 2014

Journal Articles

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Katja Klausz, PhD, Renate Burger, PhD, Christian Kellner, PhD, Pia Glorius, PhD, Andreas Guenther, MD, Matthias Peipp, PhD, Martin Gramatzki, MD

Blood (2013) 122 (21): 4442.

https://doi.org/10.1182/blood.V122.21.4442.4442

Published: 2013

Journal Articles

Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival

Andreas Guenther, MD, Renate Burger, PhD, Wolfram Klapper, Matthias Staudinger, PhD, Martin Gramatzki, MD

Blood (2013) 122 (21): 5364.

https://doi.org/10.1182/blood.V122.21.5364.5364

Published: 2013

Journal Articles

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

Matthias Staudinger, Pia Glorius, Christian Kellner, Andreas Guenther, Roland Repp, Renate Burger, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1838.

https://doi.org/10.1182/blood.V120.21.1838.1838

Published: 2012

Journal Articles

The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors

Renate Burger, Tim Bugdahn, Matthias Staudinger, Anna Lena Michaelis, Matthias Peipp, Andreas Guenther, Martin Gramatzki

Blood (2012) 120 (21): 1844.

https://doi.org/10.1182/blood.V120.21.1844.1844

Published: 2012

Journal Articles

Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth

Andreas Guenther, Renate Burger, Wolfram Klapper, MD, Matthias Staudinger, Kathrin Richter, Tanja Ahrens, Martin Gramatzki

Blood (2011) 118 (21): 2903.

https://doi.org/10.1182/blood.V118.21.2903.2903

Published: 2011

Journal Articles

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

Andreas Guenther, Renate Burger, Wolfram Klapper, Markus Tiemann, Frank Bakker, Katja Brocke-Heidrich, Friedemann Horn, Martin Gramatzki

Blood (2009) 114 (22): 1843.

https://doi.org/10.1182/blood.V114.22.1843.1843

Published: 2009

Journal Articles

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Jesús F. San-Miguel, MD, PhD, Orhan Sezer, MD, PhD, David Siegel, Andreas Guenther, MD, Maria-Victoria Mateos, MD, PhD, Ian Prosser, MBBS, FRACP, FRCPA, PhD, Michele Cavo, MD, Joan Blade, MD, Mario Boccadoro, MD, Bourras R. Bengoudifa, Martin Klebsattel, PhD, Priscille M. Bourquelot, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3852.

https://doi.org/10.1182/blood.V114.22.3852.3852

Published: 2009

Journal Articles

Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.

Andreas Guenther, Philipp Baumann, Renate Burger, Wolfram Klapper, Ralf Schmidmaier, Martin Gramatzki

Blood (2009) 114 (22): 3850.

https://doi.org/10.1182/blood.V114.22.3850.3850

Published: 2009

NARROW

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma

First Infection with Absidia Corymbifera in a CLL Patient - Ibrutinib As Risk Factor?

Reduced Intensity Vs. Myeloablative Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with Myelodysplastic Syndrome: Long Term Follow-up of a Prospective Randomized EBMT Phase III Study (RICMAC-Trial)

Immune Reconstitution after Allogeneic Stem Cell Transplantation - a Systematic Single Center Survey

Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol

The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

MSH-TP15 Identified By Phage Display Technology Detects a Target Structure For Antibody-Mediated Killing In Multiple Myeloma

Selective Inhibition Of The PI3K-Alpha Isoform Blocks Myeloma Cell Growth and Survival

The CD317-Targeted Immunotoxin HM1.24-ETA′ Efficiently Eliminates Malignant Plasma Cells in Vitro and in Vivo

The JAK1/2 Inhibitor Ruxolitinib Kills Malignant Plasma Cells and Is Synergistic with PI3K and mToR Inhibitors

Inhibitors of Mtor and PI3K Synergistically Block Plasmacytoma Cell Growth

Mtor and PI3K Inhibitors Block Myeloma Cell Growth in a Synergistic Manner.

A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma.

Phase I/II Study with Single Agent Everolimus (RAD001) in Patients with Relapsed or Refractory Multiple myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only